AcelRx Pharma (ACRX) Tops Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to AcelRx Pharma (ACRX) Tops Q2 EPS by 6c

AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results

November 6, 2019 4:05 PM EST

REDWOOD CITY, Calif., Nov. 6, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2019 financial results.

"Achieving 125 REMS-certified facilities two months ahead of our year-end goal demonstrates healthcare providers' increasing interest in DSUVIA," said Vince Angotti, Chief Executive Officer of AcelRx. "We also expect to achieve our year-end objective of 125 formulary approvals and anticipate expanded use across a variety of healthcare settings as the feedback on DSUVIA® from healthcare... More